Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Vistin Pharma ASA: Notice of Annual General Meeting 23 May 2024
Vistin Pharma ASA (OSE: VISTN), please find attached the call for the Annual General Meeting in Vistin Pharma, to be held on 23 May 2024 at 13:00 CEST.A physical Annual General Meeting will not be held. Instead, shareholders should authorize the Chairman of the Board. It is possible to give proxy with and without voting instructions. By using a proxy with voting instructions, the shareholders will vote on the specific issues without personal attendance. For further information on the use...
Nasdaq GlobeNewswire
30/04/2024
Implantica Announces Real-World Clinical Data from over 200 Patients treated…
It's a credit to the ongoing enthusiasm for RefluxStop™ to see the latest clinical data from five world-renowned European centers of excellence in the treatment of acid reflux diseases, presented at SAGES. The Centers of Excellence included the following: It's a credit to the ongoing enthusiasm for RefluxStop™ to see the latest clinical data from five world-renowned European centers of excellence in the treatment of acid reflux diseases, presented at SAGES. The Centers of Excellence included...
PR Newswire
30/04/2024
BioAro Announces a Medical and Computing Breakthrough by Launching the 'World's…
BioAro's, Founder and CEO, Dr. Anmol S. Kapoor, shared "Our team at BioAro are committed to pushing the boundaries of genomic research and technology through real-time genomic testing and analysis to provide enhanced quality of life and Healthspan. With the launch of PanOmiQ, we are ushering in a new era of precision medicine, where every patient receives tailored treatments based on their unique genetic makeup." BioAro's, Founder and CEO,Dr.Anmol S. Kapoor , shared "Our team at…
PR Newswire
30/04/2024
ViaNautis Bio appoints Dr Steven M. Altschuler as Chairman of its Board of…
ViaNautis Bio appoints Dr Steven M. Altschuler as Chairman of its Board of Directors Co-Founder of Spark Therapeutics with over 20 years of industry experience to support ViaNautis Bio in its next stage of development Cambridge UK,30 April 2024– ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking nanomedicine company at the forefront of genetic therapies, today announces the appointment of Dr Steven M. Altschuler as independent Chairman to its Board of Directors...
Nasdaq GlobeNewswire
30/04/2024
Scientific leaders gather at global summit in Denmark to advance knowledge and…
The summit is taking place on 6-7 May 2024 in Helsingør and focuses on the growing global burden of non-communicable diseases, infectious diseases, and climate change, and the interplay between them. The summit is taking place on6-7 May 2024in Helsingør and focuses on the growing global burden of non-communicable diseases, infectious diseases, and climate change, and the interplay between them. Through keynote speeches and panel discussions, participants will share insights on how...
PR Newswire
30/04/2024
Sandoz reaches agreement with Amgen resolving all patent litigation related to…
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilarsAgreement clears path for launch of Jubbonti ®and Wyost ®on May 31, 2025 or earlier under certain circumstancesJubbonti ®and Wyost ®are first and only FDA-approved biosimilars to and interchangeable with Prolia* ®and Xgeva* ® Anticipated launch further strengthens Sandoz biosimilar portfolio and...
Nasdaq GlobeNewswire
30/04/2024
Combined General Meeting of May 22, 2024 - Availability of preparatory documents
Press Release Paris – April 30, 2024– EUROAPI's shareholders are invited to attend the Combined General Meeting to be held on Wednesday May 22, 2024 at 10:00 a.m. (CET) at the Centre de Conférences Verso, 52 rue de la Victoire 75009 Paris.The notice of meeting was published at the French official legal announcement publication (BALO) on Friday April 12, 2024 (bulletin n°45) and the convening notice ( avis de convocation ) was published in the Actu-juridique.fr, a French...
Nasdaq GlobeNewswire
30/04/2024
BioSenic S.A. : Information on the total number of voting rights and shares
PRESS RELEASE – REGULATED INFORMATION Mont-Saint-Guibert, Belgium, April 30, 2024, 7.00 am CEST –BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares. The following information is published in accordance with Article 15 of the Belgian law of 2 May 2007 on the...
Nasdaq GlobeNewswire
30/04/2024
Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation
Oslo, April 30, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its first quarter 2024 results on Tuesday, May 7, 2024.The presentation can be followed as a live webcast accessed through a link on www.ultimovacs.com at 14:00 CET on Tuesday, May 7, 2024, and is scheduled to conclude at 14:55 CET. The webcast presentation will be available on the Ultimovacs website, and...
Nasdaq GlobeNewswire
30/04/2024
Clé de Peau Beauté and UNICEF Surpass Half of Three-Year Goal in First Year of…
"Over 90% of jobs worldwide have a digital component, but options remain limited or non-existent for girls, especially adolescent girls, in these male-dominated fields. We are thrilled to see such significant progress made in bridging the STEM gender gap in only the first year of our renewed partnership with Clé de Peau Beauté, and we look forward to continuing our work together to empower the next generation of girls," said UNICEF Director of Private Fundraising and Partnerships Carla…
PR Newswire
30/04/2024
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent…
Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapyTIVDAK is the first antibody-drug conjugate in this patient population to have positive overall survival data COPENHAGEN, Denmark; April 30, 2024 –Genmab A/S(Nasdaq: GMAB) andPfizer Inc.(NYSE: PFE) announced todaythe U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for...
Nasdaq GlobeNewswire
30/04/2024
Malignant Ascites Market to Observe Growth at a CAGR of 1.2% by 2034 |…
Key Takeaways from the Malignant Ascites Market Report Key Takeaways from the Malignant Ascites Market Report Discover which therapies are expected to grab the major malignant ascites market share @Malignant Ascites Market Report Malignant Ascites Overview Malignant ascites is a pathological condition stemming from various primary abdominal and non-abdominal cancers. It stands as a significant source of illness, presenting numerous complexities and treatment obstacles...
PR Newswire
29/04/2024
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
• Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology (ASH) 65th Annual Meeting • Execution of strategic collaboration and investment agreements with AstraZeneca• Cécile Chartier, Ph.D., appointed as a director of the Cellectis' Board of Directors• Drawdown of the second tranche of €15 million under the credit facility agreement entered into with the European Investment Bank...
Nasdaq GlobeNewswire
29/04/2024
Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU…
COPENHAGEN, Denmark, April 29, 2024– Bavarian Nordic A/S (OMX: BAVA) today announced the award of a contract valued at EUR 65 million to supply its MVA-BN ®smallpox vaccine to the strategic reserve within the European Union (EU) in 2025. This third, and larger order follows two previous orders, received in 2023 and delivered in 2024, for smallpox vaccines to rescEU stockpiles across Europe and will help to expand the EU's capability to respond to future biological threats and emergencies...
Nasdaq GlobeNewswire
29/04/2024
Probiotics in Animal Feed Market Size to Grow USD 5357.7 Million by 2030 at a…
Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-18H10252/Global_Probiotics_in_Animal_Feed Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-18H10252/Global_Probiotics_in_Animal_Feed Major Factors Driving the Growth of Probiotics in Animal Feed Market : Probiotics are becoming more and more popular in the animal feed industry due to several factors, including the trend towards natural alternatives, regulatory support...
PR Newswire
29/04/2024
Global Plant Stem Cell Skincare Product Market to reach a Valuation of US$ 353.9…
Download the Sample PDF report to explore key market insights and trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-19564 Download the Sample PDF report to explore key market insights and trends:https://www.futuremarketinsights.com/reports/sample/rep-gb-19564 Skincare companies are investing in unique packaging, branding, and marketing strategies to distinguish their plant stem cell skincare products and capture consumer attention. The men's skincare segment is...
PR Newswire
29/04/2024
Cancer Biomarkers Market Worth $42.0 billion | MarketsandMarkets™
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202 Browse in-depth TOC on "Cancer Biomarkers Market" 364 - Tables 53 - Figures 340 - Pages Cancer Biomarkers Market Scope: According to the profiling technology segment, the omics technology held the biggest market share for cancer biomarkers. The market forcancer biomarkershas...
PR Newswire
29/04/2024
NanoAi Technologies Unveils the NanoAi Analyzer: A Revolutionary Threat…
"The NanoAi Technologies analyzer represents a paradigm shift in threat detection," declared Craig MicklichEx-U.S. Navy SEAL and CEO of NanoAi Technologies. "This line of user-friendly devices deliver rapid and precise results, making it an invaluable tool for diverse environments." "The NanoAi Technologies analyzer represents a paradigm shift in threat detection," declaredCraig MicklichEx-U.S. Navy SEALand CEO of NanoAi Technologies. "This line of…
PR Newswire
29/04/2024
Midea RAC Unveils A7 Duct, an Easy-to-install HVAC System Perfect for Commercial…
The Midea Residential Air Conditioner Division (Midea RAC) is committed to addressing these challenges with products that are customized for installations and enhance efficiency and durability while simplifying the installation process. An upgrade of the Midea A6 Duct, the A7 Duct has been miniaturized and lightened by up to 20% in both volume and weight. The Midea Residential Air Conditioner Division (Midea RAC) is committed to addressing these challenges with products that are customized…
PR Newswire
29/04/2024
Judgment on FRH request for grace period extension
Judgment on FRH request for grace period extension Paris, 29 April 2024Casino Guichard-Perrachon S.A. (Euronext Paris: CO; ISIN: FR0000125585) hereby informs as follows: On behalf of France Retail Holdings S.à.r.l. (an entity ultimately controlled by Mr. Daniel Křetínský) (“FRH”), it is hereby announced that FRH has received on 25 April 2024 a judgment of the Enterprise Chamber of the Amsterdam Court of Appeal, the Netherlands, granting a thirty-day extension pursuant to Article 5:72(2)...
Nasdaq GlobeNewswire
29/04/2024
Bavarian Nordic Initiates Rolling Submission of Biologics License Application…
COPENHAGEN, Denmark, April 29, 2024– Bavarian Nordic A/S (OMX: BAVA) today announced that it has initiated the rolling submission process with the U.S. Food and Drug Administration (FDA) for a Biologics License Application (BLA) for the licensure of its CHIKV VLP vaccine candidate for immunization against chikungunya virus infection in individuals 12 years of age and older.Bavarian Nordic will submit additional data over the coming months, aiming to complete the BLA submission before the...
Nasdaq GlobeNewswire
29/04/2024
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase…
Next safety cohort to begin escalated dosing soon AIM ImmunoTech Inc.(NYSE American: AIM) (“AIM” or the “Company”) today announced that it has taken an essential step forward in testing the combination of AIM's Ampligen® (rintatolimod) and AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of late-stage pancreatic cancer (the “DURIPANC” study). See:ClinicalTrials.gov NCT05927142. Investigators at Erasmus Medical Center ("Erasmus MC") in the...
Nasdaq GlobeNewswire
29/04/2024
Henlius Trastuzumab Receives FDA Approval in the United States
View original content:https://www.prnewswire.co.uk/news-releases/henlius-trastuzumab-receives-fda-approval-in-the-united-states-302130046.html View original content: https://www.prnewswire.co.uk/news-releases/henlius-trastuzumab-receives-fda-approval-in-the-united-states-302130046.html
PR Newswire
29/04/2024
Newsweek Selects Caristo Diagnostics as One of World's Best Digital Health…
"Caristo is honored to be recognized by Newsweek as one of the World's Best Digital Health Companies. This recognition validates the importance of Caristo's CaRi-Heart® innovation as it for the first time gives healthcare professionals the ability to measure inflammation in the heart," said Frank Cheng, CEO of Caristo. "This recognition also speaks to the dedication and ingenuity of our team as well as our scientific, clinical and pharmaceutical industry partners around the world…
PR Newswire
29/04/2024
Altri Comunicati
